Treatment of recurrent hepatitis C post-liver transplantation
Journal Title: Annals of Hepatology - Year 2010, Vol 9, Issue 0
Abstract
Recurrent hepatitis C after liver transplantation is universal. Graft reinfection occurs rapidly, with chronic hepatitis and rapid evolution from end-stage liver disease. Within 5 years until 30% of patients with recurrent disease ultimately progress to cirrhosis, and survival of transplanted patients with recurrent hepatitis C virus has been shown to be lower than of patients transplanted for other indications. Antiviral therapy in this patient population is generally recommended, but indication, optimal timing, dose and duration of therapy are not clearly defined. There are two major indications of therapy in that patients: pre-transplant antiviral therapy aiming to prevent reinfection, and post-transplant therapy with the goal of eradicating the recurrent infection. The first is limited by poor tolerance and drug side effects, and the second achieves only sustained virologic response in 25-45% of patients. Combination therapy with PEG INF and ribavirin showed the better results. Dose reduction and interruption of therapy occurs in 30 to 60% by side effects. There are no prospective randomized trials with confidence of results. More efficacious and better tolerable antiviral therapies are needed.
Authors and Affiliations
Claudio Marroni
Keywords
Related Articles
- EP ID EP77969
- DOI -
- Views 131
- Downloads 0
title
abstrakt<br/><br/>
Heap of stones: An unusual cause for biliary colic and elevated liver function tests
A 40-year old woman presented with symptomatic intrahepatic gallstones in one liver segment only four years after cholecystectomy for cholelithiasis. Multiple small, yellow and round calculi were completely removed from...
High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity
Background &amp;amp; aims. Some phytochemicals present in coffee have a potential antioxidant role which seems to protect the human body against cardiovascular diseases, liver disease and malignancies. Nonalcoholic f...
The Changing Face of the Diagnosis of Chronic and Malignant Liver Diseases: Potential New Biomarkers
The early diagnosis of primary sclerosing cholangitis, hepatocellular carcinoma, and cholangiocarcinoma is often challenging. In a recent study in 134 patients (Arbelaiz, Hepatology 2017; 66:1125-1143), it was reported t...
Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation
Introduction and aim. Studies suggest that entecavir and lamivudine are useful as prophylactics against hepatitis B virus (HBV) reactivation in patients undergoing chemotherapy or immunosuppressive therapy, but which dr...